Literature DB >> 28024933

A Preoperative Multimarker Approach to Evaluate Acute Kidney Injury After Cardiac Surgery.

Tone B Enger1, Hilde Pleym2, Roar Stenseth3, Guri Greiff3, Alexander Wahba4, Vibeke Videm5.   

Abstract

OBJECTIVE: To investigate whether a multimarker strategy combining preoperative biomarkers representing distinct pathophysiologic pathways enhances preoperative risk assessment of acute kidney injury after cardiac surgery (CSA-AKI) and increases knowledge of underlying pathogenesis.
DESIGN: Prospective, cohort study.
SETTING: Single-center tertiary referral hospital. PARTICIPANTS: The study comprised 1,015 adults undergoing cardiac surgery with cardiopulmonary bypass.
INTERVENTIONS: CSA-AKI was defined as≥50% increase in serum creatinine concentration, absolute increase≥26 µmol/L, or new requirement for dialysis. Preoperative and perioperative information until hospital discharge was recorded. Preoperative plasma levels of C-reactive protein, terminal complement complex, neopterin, lactoferrin, N-terminal pro-brain natriuretic peptide, and cystatin C were determined using enzyme immunoassays. Biomarkers were selected based on causal hypotheses of underlying mechanisms and were related to inflammatory, hemodynamic, or renal signaling pathways.
MEASUREMENTS AND MAIN RESULTS: One hundred patients (9.9%) developed CSA-AKI. Higher baseline plasma concentrations of neopterin and N-terminal pro-brain natriuretic peptide were associated independently with CSA-AKI (p = 0.04 and p<0.001, respectively). Lower baseline plasma lactoferrin concentrations were observed in patients with CSA-AKI (p = 0.05). Compared with clinical risk assessment, addition of these biomarkers provided a slight, but significant, increment in predictive utility (area under the curve 0.81-0.83, likelihood ratio test p<0.001). A net of 12% of patients were reclassified correctly, and improved prediction was demonstrated, especially in patients with intermediate risk (56% correct reclassification).
CONCLUSIONS: Preoperative hemodynamic, renal, and immunologic function play central roles in the pathogenesis of CSA-AKI. These findings add evidence to the potential of a multimarker approach to improve preoperative prediction of CSA-AKI.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute kidney injury; cardiac surgery; preoperative biomarkers; risk prediction

Mesh:

Substances:

Year:  2016        PMID: 28024933     DOI: 10.1053/j.jvca.2016.10.005

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

Review 1.  Pterins as Diagnostic Markers of Mechanical and Impact-Induced Trauma: A Systematic Review.

Authors:  Angus Lindsay; Gregory Baxter-Parker; Steven P Gieseg
Journal:  J Clin Med       Date:  2019-09-03       Impact factor: 4.241

2.  Prognostic value of suPAR and hsCRP on acute kidney injury after cardiac surgery.

Authors:  Sebastian Roed Rasmussen; Rikke Vibeke Nielsen; Rasmus Møgelvang; Sisse Rye Ostrowski; Hanne Berg Ravn
Journal:  BMC Nephrol       Date:  2021-04-07       Impact factor: 2.388

3.  The Association of Matrix Metalloproteinases With Acute Kidney Injury Following CPB-Supported Cardiac Surgery.

Authors:  Erick D McNair; Jennifer Bezaire; Michael Moser; Prosanta Mondal; Josie Conacher; Aleksandra Franczak; Greg Sawicki; David Reid; Abass Khani-Hanjani
Journal:  Can J Kidney Health Dis       Date:  2021-07-16

4.  Pre-Operative Factors Associated with the Occurrence of Acute Kidney Injury in Patients Aged 65 Years and Over Undergoing Non-Ambulatory Non-Cardiac Surgery.

Authors:  Wendy De Guglielmo; Jean Michel Rebibou; Serge Aho; Thomas Rogier; Gilles Nuemi; Claude Girard; Eric Steinmetz; Mathieu Legendre
Journal:  Healthcare (Basel)       Date:  2022-03-16

Review 5.  The potential role of neopterin in Covid-19: a new perspective.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Khalid J Alzahrani; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Mol Cell Biochem       Date:  2021-07-28       Impact factor: 3.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.